Lancet 372(9645):12401250 [DOI] [PubMed] [Google Scholar] Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
Take our 5-minute quiz Tell us about your medical history and weight journey to see if you medically qualify for medications
Most GLP-1a weight loss and type diabetes medications require a prior authorization (PA) from the insurance provider: FDA-approved weight loss medications: Contrave, Saxenda (liraglutide), Wegovy (semaglutide) Zepbound (tirzepatide) FDA-approved Diabetes medications: Rybelsis, Victoza (liraglutide), Ozempic (semaglutide), or Mounjaro (tirzepatide) If your insurance company says that they cover FDA-approved diabetes medications, it suggests coverage for patients with type 2 diabetes
Over the past few years, several effective anti-obesity medications have been introduced, particularly for people who fail to lose weight with conservative measures alone
Retatrutides mechanism of action Retatrutides mechanism of action combines the effects of three hormones naturally produced after eating: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon
The addition of glucagon receptor activation increases energy expenditure directly, theoretically producing faster fat loss
